Literature DB >> 1362383

Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.

H Ozaki1, H Sato, M Hori, T Matsuyama, K Imai, H Yokoyama, A Kitabatake, M Inoue, T Kamada.   

Abstract

Xamoterol acts as a beta 1-adrenoceptor agonist at low sympathetic activity and as an antagonist at high activity. Although its long-term efficacy has been proven in patients with mild to moderate heart failure, it remains unclear which effect, agonism or antagonism, accounts for its long-term activity. To clarify the effect of xamoterol on cardiac sympathetic activity in daily life, 24-h R-R interval histograms were obtained during administration of xamoterol 100 mg b.d. for 1 week to 10 patients with mild to moderate heart failure. Eight normal subjects were also studied as controls. To examine the relation between the effect of xamoterol and sympathetic activity, plasma noradrenaline (NA) levels were measured under 5 graded conditions simulating daily living. Xamoterol administration significantly decreased the standard deviation of the R-R interval, both in patients with heart failure and in normal subjects. The mean R-R interval, however, was increased in patients with heart failure, relative to normal subjects. In both groups, the R-R interval histograms had two peaks, i.e. a short daytime peak and a long night-time peak. Xamoterol decreased the median of the night-time peak without changing the daytime peak in normal subjects. In contrast, it increased the median of the daytime peak without producing a significant change in the night-time peak in patients with heart failure. Levels of plasma NA were significantly higher in patients than in normal subjects under all conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362383     DOI: 10.1007/bf02285085

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Decreased spontaneous heart rate variability in congestive heart failure.

Authors:  G Casolo; E Balli; T Taddei; J Amuhasi; C Gori
Journal:  Am J Cardiol       Date:  1989-11-15       Impact factor: 2.778

2.  Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.

Authors:  E V Sørensen; O Faergeman; M A Day; H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist.

Authors:  J M Detry; P M Decoster; L A Brasseur
Journal:  Eur Heart J       Date:  1983-08       Impact factor: 29.983

4.  Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.

Authors:  H Sato; M Inoue; T Matsuyama; H Ozaki; T Shimazu; H Takeda; Y Ishida; T Kamada
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

5.  Twenty-four-hour pattern of ventricular excitation rhythm in resting normal human subjects.

Authors:  I Ninomiya; N Nishiura; K Shimomura
Journal:  Jpn J Physiol       Date:  1983

6.  A sensitive method for the determination of plasma catecholamines using liquid chromatography with electrochemical detection.

Authors:  H Hallman; L O Farnebo; B Hamberger; G Johnsson
Journal:  Life Sci       Date:  1978-09-11       Impact factor: 5.037

7.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

8.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

9.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.

Authors:  R S Engelmeier; J B O'Connell; R Walsh; N Rad; P J Scanlon; R M Gunnar
Journal:  Circulation       Date:  1985-09       Impact factor: 29.690

10.  Non-Gaussian distribution of arterial pressure and heart rate during sleep and waking in hypertensive and normotensive subjects.

Authors:  O Tochikubo; N Miyazaki; H Ochiai; Y Kaneko
Journal:  Jpn Circ J       Date:  1986-09
View more
  2 in total

1.  Pharmacological effects of concomitant administration of beta-adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of beta-blocker combined with beta-agonist.

Authors:  M Karita; H Sato; Y Koretsune; K Imai; H Ozaki; H Yokoyama; M Hori; H Takeda; M Inoue; T Kamada
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Sustained left ventricular diastolic dysfunction after exercise in patients with dilated cardiomyopathy.

Authors:  M Morikawa; H Sato; H Sato; Y Koretsune; Y Ohnishi; T Kurotobi; T Kuzuya; M Hori
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.